The DTaP vaccine market accounted for USD 3.26 Billion in 2022 and is reach USD 5.51 Billion by 2030, registering a CAGR of 6.84% through the forecast period. The DTaP vaccine market is likely to be driven by the introduction of combination vaccines recommended for immunization programs to reduce the number of injections required while fulfilling immunization compliance in infants. DTaP vaccine targets three diseases at once, namely, diphtheria, tetanus, and pertussis. The demand for D&T containing vaccines accounted for 945 million doses in 2017. In 2018, almost 86 % of infants worldwide received three doses of DTP3 (diphtheria-tetanus-pertussis 3) vaccine, saving them from infectious diseases, which could result in severe illness and disability, when these infants grow up. However, 151 000 cases of pertussis were still registered globally in 2018.
CDC recommends that infants should be given three shots of DTaP to build up high levels of protection against tetanus, whooping cough, and diphtheria. At the same time, young children should be given two booster shots to maintain that protection throughout their early childhood days. Growing efforts by global organizations to promote immunization programs, along with increasing awareness among the general public, is fuelling the demand for DTaP treatment.
Request a Sample@ https://qyresearchmedical.com/sample/119050
Diphtheria was one of the major causes of childhood death globally before the introduction of vaccines. With the success of the immunization program in the United States, diphtheria is nearly unheard of in the country. However, the disease continues to spread and cause illness around the world. In 2018, around 16,000 cases of diphtheria were registered globally and from some 264 cases, and 19 deaths from tetanus were reported in the U.S. The disease in infants are likely to rise as a preliminary data for the first quarter of 2022 indicates a substantial drop in the number of children completing three doses of DTP3 vaccine. First time in the last 28 years that the world has witnessed a reduction in the immunization coverage. The growing focus of industry players on enhancing vaccine development technology for advancements in therapeutic and immunization applications will favor the expansion of the DTaP market over the forecast period.
Disease type outlook:
Pertussis is a highly contagious respiratory tract infection which initially shows symptoms of an ordinary cold, but eventually turn more serious, mostly in infants. DTaP vaccine for the treatment of pertussis is forecast to grow at 7% by 2030 due to the safety and cost-effectiveness of the product. Diphtheria causes the build-up of a thick membrane at the back of the throat, leading to breathing disorder, paralysis, heart failure, and even death in some cases.
Tetanus is a severe illness that causes frequent painful muscle spasm in the whole body. The disease can also lead to locking the jaw, and the affected individual is unable to swallow or open their mouth— tetanus results in death in around 1 in 10 cases. As per data from the global burden of disease survey (2016), approximately 48,000-80,000 deaths occurred from tetanus globally, and the majority of cases were from resource-poor nations.
Product type outlook:
GlaxoSmithKline, a leading pharmaceutical company, got KINRIX™ approved by the U.S. Food and Drug Administration in 2008. The product was the first combination vaccine to offer protection against diphtheria, tetanus, pertussis as well as polio diseases in one shot. To date, the product is the most common and widely used in children. In terms of product type, KINRIX is estimated to account for a significant share of the overall market, registering a growth rate of 6.9% through 2030.
In 2018, North America dominated the global DTaP vaccine market and is expected to gain major traction over the analysis period on account of the presence of major key players investing in R&D activities, growing awareness, and subsequent demand for DTaP vaccines in the region.
Asia Pacific is forecast to register a significant CAGR through 2030 on account of increasing disease awareness in countries such as China and India. In 2018, China accounted for USD 21.7 million in terms of revenue in the global DTaP vaccine market. South Africa is set to register a CAGR of around 5.5% over the analysis period.
- The DTaP vaccine market accounted for USD 3.26 Billion in 2022 and is reach USD 5.51 Billion by 2030, registering a CAGR of 6.84% through the forecast period.
- Factors such as the introduction of combination vaccines, enhancement of vaccine development technology, and favorable R&D scenario will drive industry growth.
- The demand for D&T containing vaccines accounted for 945 million doses in 2017.
- In 2018, around 151 000 cases of pertussis were registered globally.
- DTaP vaccine for the treatment of pertussis is forecast to grow at 7% through 2030 due to the safety and cost-effectiveness of the product.
- KINRIX is estimated to account for a significant share of the overall market, registering a growth rate of 6.9% through 2030.
- Asia Pacific is forecast to register a significant CAGR through 2030 on account of increasing disease awareness in countries such as China and India. In 2018, China accounted for USD 21.7 million in terms of revenue in the global DTaP vaccine market.
- South Africa is set to register a CAGR of around 5.5% over the analysis period.
- Industry players are investing in the development of combination vaccines to offer standardized immunization treatments.
The companies profiled in the report are GlaxoSmithKline, Sanofi Pasteur, Protein Sciences Corporation, Novartis AG, Merch Sharp & Dohme Corp., Pfizer Inc., Astellas Pharma US, Sanofi Aventis, AstraZeneca, and Emergent Biosolution Inc. These industry players are focusing on developing combination vaccines to lower disease burden globally.
In 2017, Sanofi Pasteur introduced Quadracel vaccine (DTaP and Inactivated Poliovirus), which was approved by the FDA for immunization to combat diphtheria, tetanus, pertussis, poliomyelitis in children aged 4-6 years. CDC then claimed that it could also lead to astonishingly fewer vaccine shots, which aid in facilitating process standardization, enhance staff efficiency, and thereby preventing administration errors.
Segments Covered in the report:
This report forecasts revenue growth at a global, regional & country level and provides an analysis of the industry trends in each of the sub-segments from 2022 to 2030. For the purpose of this study, Reports and Data has segmented the Global DTaP Vaccine Market on the basis of disease type, product type, end-user, and region:
Disease Type Outlook (Volume, Kilo Tons; Revenue, USD Million; 2022-2030)
Product Type Outlook (Volume, Kilo Tons; Revenue, USD Million; 2022-2030)
End-user Outlook (Volume, Kilo Tons; Revenue, USD Million; 2022-2030)
- Vaccination Centers
Regional Outlook (Volume, Kilo Tons; Revenue, USD Million; 2022-2030)
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119050/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: